GleamWall
中文EN

VNRX VOLITIONRX LTD

In Vitro & In Vivo Diagnostic Substances · NYSE · SEC CIK 93314 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY134.0%
TTM net income YoY-3.8%
TTM EPS YoY62.7%
Revenue 3-yr CAGR74.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-512.6%
Net margin-698.5%
FCF margin-597.6%
EBITDA margin-489.2%

Returns

ROE—
ROA-352.5%
ROIC (approx.)—
Asset turnover0.50x

Leverage & solvency

Liabilities / assets481.7%
Debt / equity—
Current ratio0.33x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-51.9%
Payout ratio—
Capex / revenue2.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.61M$398,657$985,076$447,034$627,277$406,688$246,385$191,657
R&D expense$1.99M$1.80M$2.85M$2.47M$2.29M$2.72M$2.61M$2.59M
SG&A expense$2.38M$2.21M$2.63M$1.80M$2.48M$2.94M$2.24M$2.13M
Operating income-$3.33M-$4.16M-$5.35M-$4.82M-$5.10M-$6.30M-$5.52M-$5.78M
Interest expense$142,816$740,388$125,842—$143,800$123,356$96,669—
Net income-$3.80M-$7.33M-$6.66M-$6.27M-$5.38M-$6.28M-$5.42M-$6.08M
EBITDA-$3.16M-$3.97M-$5.14M-$4.59M-$4.85M-$6.05M-$5.27M-$5.49M
EPS (diluted)-0.21-0.85-0.97—-0.99-1.22-1.12—
Weighted avg. shares (diluted)18.90M9.15M6.88M—5.41M5.13M4.83M—
Balance sheet
Cash & equivalents$2.40M$2.80M$3.10M$1.12M$199,407$2.26M$2.60M$3.26M
Receivables$182,629$277,355$252,242$317,808$309,085$189,597$187,830$110,574
Current assets$3.23M$4.09M$4.52M$2.06M$1.33M$3.26M$3.29M$4.06M
PP&E, net$3.41M$3.56M$3.77M$4.03M$4.24M$4.50M$4.35M$4.43M
Intangibles$297,052$305,133$318,901$316,704$301,033$306,377$317,129$313,747
Total assets$7.20M$8.30M$9.04M$6.90M$6.45M$8.70M$8.52M$9.40M
Current liabilities$9.89M$13.49M$13.57M$12.23M$11.42M$9.24M$8.27M$7.79M
Short-term debt$1.99M$1.07M$940,258$890,571$913,582$1.02M$862,475$860,223
Long-term debt$4.72M$5.98M$6.35M$5.82M$5.57M$5.77M$5.53M$3.95M
Total debt$6.71M$7.05M$7.29M$6.71M$6.48M$6.79M$6.39M$4.81M
Total liabilities$34.70M$41.84M$42.40M$42.49M$42.40M$41.80M$37.55M$35.51M
Shareholders' equity-$26.12M-$32.16M-$31.97M-$34.25M-$34.64M-$31.82M-$27.77M-$24.91M
Net debt$4.31M$4.25M$4.19M$5.59M$6.28M$4.53M$3.79M$1.55M
Shares outstanding32.81M12.04M7.93M6.29M109.62M103.98M100.75M96.10M
Cash flow statement
Operating cash flow-$4.59M-$5.16M-$5.28M-$5.49M-$3.63M-$6.26M-$4.30M-$5.43M
Capital expenditure$46,940$1,788$9,214$10,967$0$76,783$1,808$72,601
Free cash flow-$4.63M-$5.16M-$5.29M-$5.50M-$3.63M-$6.34M-$4.30M-$5.50M
Investing cash flow-$46,940-$1,788-$9,214-$10,967$0-$76,783-$1,808-$197,859
Financing cash flow$4.34M$4.98M$7.62M$6.16M$1.60M$5.67M$3.67M$2.29M
Depreciation & amortization$178,845$188,013$207,371$230,824$248,253$252,688$251,941$295,642
Stock-based compensation$186,948$238,004$224,981-$132,875$609,167$812,045$451,374$325,738
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 63 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.